[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iglon5\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iglon5":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100603176",false,"NCT07133113","Medium-term Effects of Treatments in Autoimmune Encephalitis","Medium-term Effects of Treatments in Autoimmune Encephalitis (META): a Real-life, Observational Prospective Study","META","Inclusion Criteria:\n\n* Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP\n* Untreated or with a decision to treat within the previous 30 days.\n\nExclusion Criteria:\n\n\\- Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his\u002Fher clinical data.","ALL",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL","Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immunosuppression (rituximab and cyclophosphamide). Absence of clear response to initial treatment in the first 4 to 6 weeks may indicate undertreatment and is generally followed by treatment escalation, mostly to dual immunosuppression. However, as the frequency of non-responders to initial treatment is unknown, it is still unclear whether dual immunosuppression should be offered to all patients from inception.",[23,24,25,26,27,28],"NMDAR Autoimmune Encephalitis","LGI1 Antibody Associated Encephalitis","CASPR2-Antibody","IgLON5","GAD65","GFAP",[30,31],"Paraneoplastic neurological disorder","autoimmune encephalitis","RECRUITING","2025-08-13",{"date":35,"type":36},"2025-08-20","ACTUAL",{"date":38,"type":36},"2024-09-01",{"date":40,"type":19},"2027-03-01",{"name":42,"class":43},"Hospices Civils de Lyon","OTHER",""]